X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
LYT-100 (deupirfenidone) is an inhibitor of IL-6 and TNF alpha. It is being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.
Lead Product(s): Deupirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LYT-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
LYT-100 (deupirfenidone) was well-tolerated compared to pirfenidone in a healthy older adult crossover trial, informing dose selection for recently initiated trial in IPF.
Lead Product(s): Deupirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LYT-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
IPF study will evaluate efficacy of two doses of LYT-100 (deupirfenidone), one with comparable exposure to FDA-approved dose of pirfenidone and one with higher exposure, vs. placebo, as well as relative tolerability and efficacy vs. pirfenidone.
Lead Product(s): Deupirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LYT-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
No treatment effect observed in this patient population for LYT-100-COV (deupirfenidone) substantial improvement in 6-minute walk test seen in both placebo and active groups.
Lead Product(s): Deupirfenidone
Therapeutic Area: Infections and Infectious Diseases Product Name: LYT-100-COV
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
Further data from Phase 1 study in healthy older adults demonstrate improved tolerability profile of LYT-100 (deupirfenidone), a deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, compared to pirfenidone.
Lead Product(s): Deupirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LYT-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
A dose-proportional PK profile was observed with LYT-100 throughout the range of doses studied. In the single ascending food effect cohort, exposure was slightly lower in the fed condition.
Lead Product(s): Deupirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LYT-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2021
Details:
Study will further evaluate safety and tolerability of LYT-100 and explore clinical efficacy endpoints in paƟents with breast-cancer related, upper limb secondary lymphedema.
Lead Product(s): Deupirfenidone
Therapeutic Area: Immunology Product Name: LYT-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
LYT-100 is a deuterated, oral small molecule designed to overcome the challenges associated with pirfenidone, an approved and marketed anti-inflammatory and anti-fibrotic drug. Phase 2 trial will evaluate LYT-100 in Long COVID respiratory complications and related sequelae.
Lead Product(s): Deupirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LYT-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
The global, randomized, placebo-controlled trial is expected to begin in Q3 2020 and will evaluate LYT-100 in non-critical COVID-19 patients with respiratory complications.
Lead Product(s): Deupirfenidone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
